RIGEL PHARMACEUTICALS, INC. Interest Expense
RIGEL PHARMACEUTICALS, INC. (RIGL) reported Interest Expense of $1.89 million for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-04.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpense · last filed 2025-11-04
- RIGEL PHARMACEUTICALS, INC. interest expense for the quarter ending 2025-09-30 was $1.89M, a 8.06% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. interest expense for the quarter ending 2025-06-30 was $1.87M, a 7.64% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. interest expense for the quarter ending 2025-03-31 was $1.85M, a 1.12% decline year-over-year.
- RIGEL PHARMACEUTICALS, INC. interest expense for the quarter ending 2024-12-31 was $1.96M, a 2.52% increase year-over-year.
- RIGEL PHARMACEUTICALS, INC. interest expense for fiscal 2024 was $7.92M, a 15.22% increase from fiscal 2023.
- RIGEL PHARMACEUTICALS, INC. interest expense for fiscal 2023 was $6.87M, a 85.38% increase from fiscal 2022.
- RIGEL PHARMACEUTICALS, INC. interest expense for fiscal 2022 was $3.71M, a 23.72% decline from fiscal 2021.
- RIGEL PHARMACEUTICALS, INC. interest expense for fiscal 2021 was $4.86M, a 259.20% increase from fiscal 2020.
| Period end | Interest Expense 3 month | Interest Expense 6 month | Interest Expense 9 month | Interest Expense 12 month |
|---|---|---|---|---|
| 2025-09-30 | $1.89M 10-Q · filed 2025-11-04 | $3.77M derived: sum of 2 quarters · filed 2025-11-04 | $5.62M 10-Q · filed 2025-11-04 | $7.58M derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-06-30 | $1.87M 10-Q · filed 2025-08-05 | $3.73M 10-Q · filed 2025-08-05 | $5.68M derived: sum of 3 quarters · filed 2025-08-05 | $7.74M derived: sum of 4 quarters · filed 2025-11-04 |
| 2025-03-31 | $1.85M 10-Q · filed 2025-05-06 | $3.81M derived: sum of 2 quarters · filed 2025-05-06 | $5.87M derived: sum of 3 quarters · filed 2025-11-04 | $7.90M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-12-31 | $1.96M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $4.01M derived: sum of 2 quarters · filed 2025-11-04 | $6.04M derived: sum of 3 quarters · filed 2025-11-04 | $7.92M 10-K · filed 2025-03-04 |
| 2024-09-30 | $2.06M 10-Q · filed 2025-11-04 | $4.09M derived: sum of 2 quarters · filed 2025-11-04 | $5.96M 10-Q · filed 2025-11-04 | $7.87M derived: sum of 4 quarters · filed 2025-11-04 |
| 2024-06-30 | $2.03M 10-Q · filed 2025-08-05 | $3.90M 10-Q · filed 2025-08-05 | $5.81M derived: sum of 3 quarters · filed 2025-08-05 | $7.71M derived: sum of 4 quarters · filed 2025-08-05 |
| 2024-03-31 | $1.87M 10-Q · filed 2025-05-06 | $3.78M derived: sum of 2 quarters · filed 2025-05-06 | $5.68M derived: sum of 3 quarters · filed 2025-05-06 | $7.54M derived: sum of 4 quarters · filed 2025-05-06 |
| 2023-12-31 | $1.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $3.81M derived: sum of 2 quarters · filed 2025-03-04 | $5.67M derived: sum of 3 quarters · filed 2025-03-04 | $6.87M 10-K · filed 2025-03-04 |
| 2023-09-30 | $1.90M 10-Q · filed 2024-11-07 | $3.76M derived: sum of 2 quarters · filed 2024-11-07 | $4.96M 10-Q · filed 2024-11-07 | $6.07M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $1.86M 10-Q · filed 2024-08-06 | $3.07M 10-Q · filed 2024-08-06 | $4.17M derived: sum of 3 quarters · filed 2025-03-04 | $5.00M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | $1.20M 10-Q · filed 2024-05-07 | $2.31M derived: sum of 2 quarters · filed 2025-03-04 | $3.14M derived: sum of 3 quarters · filed 2025-03-04 | $3.71M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $1.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $1.93M derived: sum of 2 quarters · filed 2025-03-04 | $2.50M derived: sum of 3 quarters · filed 2025-03-04 | $3.71M 10-K · filed 2025-03-04 |
| 2022-09-30 | $826.00K 10-Q · filed 2023-11-07 | $1.40M derived: sum of 2 quarters · filed 2023-11-07 | $2.60M 10-Q · filed 2023-11-07 | $3.90M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $569.00K 10-Q · filed 2023-08-01 | $1.77M 10-Q · filed 2023-08-01 | $3.07M derived: sum of 3 quarters · filed 2024-03-05 | $4.39M derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $1.21M 10-Q · filed 2023-05-02 | $2.50M derived: sum of 2 quarters · filed 2024-03-05 | $3.82M derived: sum of 3 quarters · filed 2024-03-05 | $5.58M derived: sum of 4 quarters · filed 2024-03-05 |
| 2021-12-31 | $1.30M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | $2.62M derived: sum of 2 quarters · filed 2024-03-05 | $4.38M derived: sum of 3 quarters · filed 2024-03-05 | $4.86M 10-K · filed 2024-03-05 |
| 2021-09-30 | $1.32M 10-Q · filed 2022-11-03 | $3.08M derived: sum of 2 quarters · filed 2022-11-03 | $3.56M 10-Q · filed 2022-11-03 | $3.99M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-06-30 | $1.76M 10-Q · filed 2022-08-02 | $2.24M 10-Q · filed 2022-08-02 | $2.67M derived: sum of 3 quarters · filed 2023-03-07 | $3.10M derived: sum of 4 quarters · filed 2023-03-07 |
| 2021-03-31 | $485.00K 10-Q · filed 2022-05-03 | $914.00K derived: sum of 2 quarters · filed 2023-03-07 | $1.34M derived: sum of 3 quarters · filed 2023-03-07 | $1.70M derived: sum of 4 quarters · filed 2023-03-07 |
| 2020-12-31 | $429.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-07 | $858.00K derived: sum of 2 quarters · filed 2023-03-07 | $1.21M derived: sum of 3 quarters · filed 2023-03-07 | $1.35M 10-K · filed 2023-03-07 |
| 2020-09-30 | $429.00K 10-Q · filed 2021-11-02 | $782.00K derived: sum of 2 quarters · filed 2021-11-02 | $924.00K 10-Q · filed 2021-11-02 | $1.25M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-06-30 | $353.00K 10-Q · filed 2021-08-03 | $495.00K 10-Q · filed 2021-08-03 | $822.00K derived: sum of 3 quarters · filed 2022-03-01 | $830.00K derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-03-31 | $142.00K 10-Q · filed 2021-05-05 | $469.00K derived: sum of 2 quarters · filed 2022-03-01 | $477.00K derived: sum of 3 quarters · filed 2022-03-01 | |
| 2019-12-31 | $327.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $335.00K derived: sum of 2 quarters · filed 2022-03-01 | $335.00K 10-K · filed 2022-03-01 | |
| 2019-09-30 | $8.00K 10-Q · filed 2020-11-05 | $8.00K 10-Q · filed 2020-11-05 | ||
| 2012-03-31 | $0.00 10-Q · filed 2012-05-01 | $3.00K derived: sum of 2 quarters · filed 2014-03-04 | $7.00K derived: sum of 3 quarters · filed 2014-03-04 | $14.00K derived: sum of 4 quarters · filed 2014-03-04 |
| 2011-12-31 | $3.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-04 | $7.00K derived: sum of 2 quarters · filed 2014-03-04 | $14.00K derived: sum of 3 quarters · filed 2014-03-04 | $25.00K 10-K · filed 2014-03-04 |
| 2011-09-30 | $4.00K 10-Q · filed 2012-11-06 | $11.00K derived: sum of 2 quarters · filed 2012-11-06 | $22.00K 10-Q · filed 2012-11-06 | $43.00K derived: sum of 4 quarters · filed 2013-03-05 |
| 2011-06-30 | $7.00K 10-Q · filed 2012-08-07 | $18.00K 10-Q · filed 2012-08-07 | $39.00K derived: sum of 3 quarters · filed 2013-03-05 | $54.00K derived: sum of 4 quarters · filed 2013-03-05 |
| 2011-03-31 | $11.00K 10-Q · filed 2012-05-01 | $32.00K derived: sum of 2 quarters · filed 2013-03-05 | $47.00K derived: sum of 3 quarters · filed 2013-03-05 | $72.00K derived: sum of 4 quarters · filed 2013-03-05 |
| 2010-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-05 | $36.00K derived: sum of 2 quarters · filed 2013-03-05 | $61.00K derived: sum of 3 quarters · filed 2013-03-05 | $91.00K 10-K · filed 2013-03-05 |
| 2010-09-30 | $15.00K 10-Q · filed 2011-11-01 | $40.00K derived: sum of 2 quarters · filed 2011-11-01 | $70.00K 10-Q · filed 2011-11-01 | |
| 2010-06-30 | $25.00K 10-Q · filed 2011-08-02 | $55.00K 10-Q · filed 2011-08-02 | ||
| 2009-12-31 | $203.00K 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |